Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Cite this article
The Approach to Small Vessels in the Era of Drug-Eluting Stents
1 Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN
2020 The Lindner Center for Research and Education, The Ohio Heart and Vascular Center, Inc., at The Christ Hospital, Cincinnati, OH
Rev. Cardiovasc. Med. 2005, 6(S1), 31–37;
Published: 20 January 2005
The treatment of small-vessel disease will occupy an increasingly important part of interventional cardiology practice and this raises several issues. The definition of “small vessels” has great implications for device size selection, and knowledge of “normal” small-vessel dimensions is important. Stents have been applied in the setting of smaller-vessel disease and future iterations of small-vessel stents will need to address several design factors. Stent strut thickness might impact on subsequent restenosis as well as late lumen loss. There has been great interest in the use of drugeluting stents for small vessels. Randomized clinical trials of sirolimus-eluting versus bare metal stents in the treatment of small-vessel disease have shown significant improvements in the rates of target lesion revascularization and restenosis with sirolimus-eluting stents. These improvements in restenosis rates are attributable to the low levels of late loss with the drug-eluting stent.